On the International Day of Happiness, Finland Calls for International Business Cooperation to Solve Major Global Challenges Together
Societal stability, high levels of equality and, among other things, political and civil freedom are frequently highlighted as the key factors contributing to Finland's status as the world’s happiest country in recent years, as reflected in the World Happiness Report. These are the building blocks of the trust and mutual respect that permeate Finnish society, enabling innovative international cooperation and providing an excellent launchpad for business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319812998/en/
Photo credits: Svante Gullichsen & Visit Finland
In Finnish society, there are many factors that underscore succeeding together: an education system that emphasizes teamwork and collective problem-solving, flat hierarchies in organizations and a society that encourages participation, a culture that values consensus and cooperation over individual competition, and social safety nets that provide security, allowing for risk-taking. This creates an environment where it is safe to engage in innovation and seize the opportunities life offers.
Collaboration is the power to change the world
The strong collaboration between the public and private sectors forms the backbone of Finland’s innovation economy. Industries, research institutes, universities, and the government together have a unique ability to deliver disruptive technologies and innovative design. Finland consistently ranks among the world’s leading countries in education, innovation, digitalization, sustainability, and good governance, making it one of the world’s hotspots for R&D. To give it a further boost, Finland aims to increase research and development expenditure to 4% of GDP by 2030.
Finland boasts a thriving startup scene with an estimated number of 3 800 startups. The Finnish startup ecosystem has always been about pooling resources, lending a hand, and helping one another. When one business is successful, it benefits the whole network – a rising tide lifts all boats. Finland's startup ecosystem has given birth to more than 10 unicorns, many of which stem from academia.
An example of open-minded cooperation in building R&D is the Leading Companies Program. Here, Business Finland challenges global companies to undertake ambitious research efforts while encouraging companies of different sizes and other players to work together, sharing knowledge and resources, aiming to achieve breakthroughs that solve major global challenges – and do business. So far, the scheme has supported 400 companies in Finland and 400 research projects by universities and other research institutes. The Leading Companies Program is open to international companies that have a subsidiary in Finland.
Finland invites you to innovate in the state of happiness
Collaboration with Finns is defined by sisu – a uniquely Finnish concept of integrity-driven determination and courage under pressure. It means acting with deep resolve while upholding a strong commitment to mutual respect among collaborators. Promises are kept, and things are done well even when no one is watching.
Johanna Jäkälä, Executive Director, Finland Promotion Services from Business Finland says:
“Collaboration, along with sisu, is really in the DNA of Finland. No one creates change alone, and that is why we are committed to bringing people and businesses together to team up, make unexpected connections, solve problems together, and create an impact.”
For the 8th year in a row, Finland has been named the happiest country in the world by the annual United Nations World Happiness Report*, holding the top title since 2018.
ABOUT
Business Finland is the Finnish government organization for innovation funding and trade, travel, and investment promotion. Business Finland’s over 760 experts work in over 40 offices globally and in 16 regional offices around Finland. Business Finland is part of the Team Finland network. www.businessfinland.com
Invest in Finland helps foreign companies identify business opportunities in Finland, produces information on Finland as an investment destination, and enhances and coordinates national efforts to attract investment by actively networking with regional and international entities. Invest in Finland also collects and updates information about foreign-owned companies in Finland. Invest in Finland is part of Business Finland.
Work in Finland attracts talents and startup founders to Finland and help companies to recruit international professionals. www.workinfinland.com is a national website for talent attraction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319812998/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom